ProfileGDS5678 / 1454917_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 80% 80% 78% 80% 80% 81% 77% 80% 81% 80% 80% 81% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.6672880
GSM967853U87-EV human glioblastoma xenograft - Control 25.639280
GSM967854U87-EV human glioblastoma xenograft - Control 35.6565980
GSM967855U87-EV human glioblastoma xenograft - Control 45.4847178
GSM967856U87-EV human glioblastoma xenograft - Control 55.7377280
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.4498780
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.6587881
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.2285177
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.6331980
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.8546181
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.6668580
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.6962880
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.8341281
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.6513180